Attovia Therapeutics (ATTO) FDA Approvals $17.14 -1.02 (-5.62%) Closing price 04:00 PM EasternExtended Trading$17.12 -0.02 (-0.09%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Share Share FDA Events Stock AnalysisAnalyst ForecastsChartEarningsFDA EventsInsider TradesNews and TrendsSEC Filings Attovia Therapeutics' Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Attovia Therapeutics (ATTO). Over the past two years, Attovia Therapeutics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as ATTO-1310. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. ATTO-1310 FDA Regulatory Events ATTO-1310 is a drug developed by Attovia Therapeutics for the following indication: in patients with high-itch atopic dermatitis (AD) or with chronic pruritus. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Data Presentation - September 28,2026Data Presentation Drug: ATTO-1310Announced Date: September 28, 2026Indication: in patients with high-itch atopic dermatitis (AD) or with chronic pruritusAnnouncementAttovia Therapeutics, Inc. announced that it will present new clinical, translational, and preclinical data across its pipeline at the European Academy of Dermatology and Venereology (EADV) Congress 2026 and the Fall Clinical Dermatology Conference (FCD) 2026.Read Announcement Attovia Therapeutics FDA Events - Frequently Asked Questions Has Attovia Therapeutics received FDA approval? As of now, Attovia Therapeutics (ATTO) has not received any FDA approvals for its therapy in the last two years. What drugs has Attovia Therapeutics submitted to the FDA? In the past two years, Attovia Therapeutics (ATTO) has reported FDA regulatory activity for ATTO-1310. What is the most recent FDA event for Attovia Therapeutics? The most recent FDA-related event for Attovia Therapeutics occurred on September 28, 2026, involving ATTO-1310. The update was categorized as "Data Presentation," with the company reporting: "Attovia Therapeutics, Inc. announced that it will present new clinical, translational, and preclinical data across its pipeline at the European Academy of Dermatology and Venereology (EADV) Congress 2026 and the Fall Clinical Dermatology Conference (FCD) 2026." What conditions do Attovia Therapeutics' current drugs treat? Currently, Attovia Therapeutics has one therapy (ATTO-1310) targeting the following condition: in patients with high-itch atopic dermatitis (AD) or with chronic pruritus. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events ANI Pharmaceuticals FDA EventsCandel Therapeutics FDA EventsCelcuity FDA EventsConnect Biopharma FDA EventsCytosorbents FDA EventsDiaMedica Therapeutics FDA EventsEupraxia Pharmaceuticals FDA EventsJade Biosciences FDA EventsKailera Therapeutics FDA EventsSatellos Bioscience FDA EventsQ32 Bio FDA EventsSol-Gel Technologies FDA EventsSilexion Therapeutics FDA EventsSarepta Therapeutics FDA EventsTiziana Life Sciences FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:ATTO last updated on 9/29/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredNot SpaceX. Not Tesla. Smaller.SpaceX isn't public, but its paperwork references a company trading for about 14 dollars a share. Roughly 4,40...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Attovia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Attovia Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Data Presentation - September 28,2026Data Presentation Drug: ATTO-1310Announced Date: September 28, 2026Indication: in patients with high-itch atopic dermatitis (AD) or with chronic pruritusAnnouncementAttovia Therapeutics, Inc. announced that it will present new clinical, translational, and preclinical data across its pipeline at the European Academy of Dermatology and Venereology (EADV) Congress 2026 and the Fall Clinical Dermatology Conference (FCD) 2026.Read Announcement
